New York, NYNCT05057702Now EnrollingIRB Ready

Medulloblastoma Clinical Trial in New York, NY

Access cutting-edge medulloblastoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access medulloblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related medulloblastoma treatment provided free

Apply for This New York Location

Check if you qualify for this medulloblastoma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Medulloblastoma Study in New York

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Participants must have recurrent medulloblastoma or recurrent ependymoma previously histologically confirmed. Participants must be experiencing their first or second relapse to be eligible.
Participants must have surgically accessible disease.
Prior Therapy:
The participant must have received at least one prior therapy at the time of initial diagnosis.
Relapsed medulloblastoma or relapsed ependymoma are eligible.
Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and would be eligible for surgical resection per institutional guidelines
Participants must have received last chemotherapy or biologic agent at least 7 days prior to registration.
Monoclonal antibody treatment: \> 21 days prior to registration.
Bevacizumab participants must have received last dose \> 21 days prior to study registration
Participant must be a candidate for surgical resection or biopsy with anticipated ability to obtain the minimum tissue requirements for study.
Radiation - Participants must have:
Had their last fraction of local irradiation to primary tumor \>= 12 weeks prior to registration.
Had their last fraction of craniospinal irradiation or total body irradiation \>= 12 weeks prior to registration
At least 14 days after local palliative radiation (small-port)
Age \>=12 months to \<= 39 years of age.
Karnofsky \>= 50 for participants \> 16 years of age and Lansky \>= 50 for participants \<= 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Corticosteroids: Participants who are receiving dexamethasone or equivalent must be on a stable or decreasing dose for at least 1 week prior to registration.
Organ Function Requirements (within 7 days prior to study registration)
Adequate Bone Marrow Function Defined as:
Peripheral absolute neutrophil count (ANC) \>= 750/mm\^3
Platelet count \>= 75,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).
Hemoglobin \>= 8 g/dl.
Adequate Renal Function Defined as:
Creatinine clearance or radioisotope GFR \>= 70 milliliter/minute (mL/min) /1.73 m\^2 or
A serum creatinine based on age/sex as follows: Age / Maximum Serum Creatinine (mg/dL) Male / Maximum Serum Creatinine (mg/dL) Female.
1 to \< 2 years / 0.6 / 0.6.
2 to \< 6 years / 0.8 / 0.8.
6 to \< 10 years / 1 / 1.
10 to \< 13 years / 1.2 / 1.2.
13 to \< 16 years / 1.5 / 1.4.
\>= 16 years / 1.7 / 1.4.
\- The threshold creatinine values in this table were derived from the Schwartz formula for estimating Glomerular filtration rate (GFR) utilizing child length and stature data published by the Center for Disease Control (CDC) (Schwartz GJ and Gauthier B 1985).
Adequate Liver Function Defined as:
Total Bilirubin \<= 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin \< 3 x ULN or direct bilirubin \< 1.5 x ULN.
Alanine aminotransferase (ALT) \<= 3x ULN.
Aspartate aminotransferase (AST) \<= 3x ULN.
The effects of the agents used in this study on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of therapy administration. Should a woman become pregnant or suspect pregnancy while participating in this study, the treating physician should be informed immediately.
Adequate neurologic function defined as participants with seizure disorder may be enrolled if seizures are well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.
Participants must enroll on the Protocol for Children and Young Adults Diagnosed with a Central Nervous System (CNS) Tumor to Assess Cognitive, Quality of Life (QOL), and Comprehensive Effects of Therapies (PNOC COMP) study if PNOC COMP is open to accrual at the enrolling institution
A legal parent/guardian or participant must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.

Exclusion Criteria

Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
Participants who are receiving any other investigational agents.
Participants must be at least 7 days since the completion of therapy with a biologic or small molecule agent. For any agent with known adverse events that can occur beyond 7 days after administration, the period prior to enrollment must be beyond the time during which adverse events are known to occur. Such participants should also be discussed with study chairs.
Participants who are currently taking any anti-cancer direct therapy. Steroids are not considered anti-cancer therapy.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required prior to start of therapy.
Participants must not receive any tumor-directed therapy after enrollment, except for surgical resection/ biopsy. Important note: The eligibility criteria listed above are interpreted literally and cannot be waived.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05057702) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Medulloblastoma Treatment Options in New York, NY

If you're searching for medulloblastoma treatment options in New York, NY, this clinical trial (NCT05057702) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced medulloblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all medulloblastoma clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in New York, NY

See all ankylosing spondylitis clinical trials recruiting in New York — not just this study.

Browse Ankylosing Spondylitis Trials in New York →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsErectile Dysfunction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY